Pfizer reports positive Phase 2 topline results for next-generation CDK4 inhibitor atirmociclib in second-line metastatic breast cancer Pfizer Inc. today announced positive topline results from the randomized Phase 2 FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant or…
Allergan Aesthetics Introduces New Skin Quality Index to Transform How Skin Health Is Measured and Communicated Allergan Aesthetics, an AbbVie company, today announced the launch of the Skin Quality Index (SQI), a unified vocabulary developed to standardize how patients and…
Eli Lilly and Company Issues Open Letter Warning About Potential Patient Safety Risks of Tirzepatide Compounded with Vitamin B12 Lilly is issuing a public warning about potential safety risks associated with compounded tirzepatide mixed with vitamin B12. As part of…
GoodRx Partners with Viatris to Offer Up to 85% Savings on Established Brand Medications GoodRx the leading platform for prescription savings in the U.S., announced a new collaboration with Viatris, a global healthcare company, to make 17 of its established…
Veristat Expands Regulatory and Clinical Services to Chinese Drug and Device Companies Seeking Efficient Way to Enter European Markets Veristat, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced expanded regulatory and clinical trial services to…
Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy Vertex Pharmaceuticals Incorporated today announced positive data from a pre-specified Week 36 interim…
First Patient Dosed in Emalex Biosciences’ Expanded Access Program for Investigational Tourette Syndrome Therapy Emalex Biosciences today announced that the first patient was dosed in its Expanded Access Program for ecopipam, an investigational first-in-class D1 receptor antagonist in development for…
Obesity Drug Olatorepatide, Licensed by Regeneron Pharmaceuticals, Shows Positive Phase 3 Outcomes in Chinese Patients Regeneron Pharmaceuticals, Inc. today announced Hansoh Pharmaceutical Group Company Limited has shared positive topline data from its Phase 3 trial in Chinese patients evaluating olatorepatide for the…
Bristol Myers Squibb Reports Positive Phase 3 SUCCESSOR-2 Trial Results for Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma Bristol Myers Squibb (NYSE: BMY) today announced positive interim Phase 3 results from the SUCCESSOR-2 study (NCT05552976). In the trial, oral mezigdomide…
Pfizer Reports Positive Phase 2 Results for Trispecific Antibody in Moderate-to-Severe Atopic Dermatitis Pfizer Inc. today announced positive topline results from a Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate to severe atopic dermatitis. The study met its…
Enhertu receives U.S. Priority Review as a post-neoadjuvant therapy for patients with early-stage HER2-positive breast cancer. AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has been accepted and granted Priority Review in the US for the treatment…
AbbVie reports positive topline results from a Phase 1 multiple ascending dose study of ABBV-295, a long-acting amylin analog evaluated in adults. AbbVie (NYSE: ABBV) today announced positive topline results1 from the multiple ascending dose (MAD) part of its Phase 1…